Guard Therapeutics: Overlooked Opportunity
Redeye reinforces its positive stance on Guard following a transfer of coverage and a review of the case. We regard the shares as fundamentally undervalued and believe the market fails to recognise the company’s progress in clinical advancements. Our base case of SEK 3. 0 per share implies +100% upside potential.